| 1 |
35251319 | Overview of systemic therapy options in liposarcoma, with a focus on the activity of selinexor, a selective inhibitor of nuclear export in dedifferentiated liposarcoma. | 2022 |
1 |
| 2 |
33507295 | Salicylates enhance CRM1 inhibitor antitumor activity by induction of S-phase arrest and impairment of DNA-damage repair. | 2021 Jan 28 |
2 |
| 3 |
34340703 | PSPC1 is a new contextual determinant of aberrant subcellular translocation of oncogenes in tumor progression. | 2021 Aug 2 |
1 |
| 4 |
34583979 | Rational Combination of CRM1 Inhibitor Selinexor and Olaparib Shows Synergy in Ovarian Cancer Cell Lines and Mouse Models. | 2021 Dec |
1 |
| 5 |
31133853 | A CRM1 Inhibitor Alleviates Cardiac Hypertrophy and Increases the Nuclear Distribution of NT-PGC-1α in NRVMs. | 2019 |
1 |
| 6 |
29707241 | KPT-330 inhibition of chromosome region maintenance 1 is cytotoxic and sensitizes chronic myeloid leukemia to Imatinib. | 2018 |
5 |
| 7 |
29866745 | The XPO1 Inhibitor Selinexor Inhibits Translation and Enhances the Radiosensitivity of Glioblastoma Cells Grown In Vitro and In Vivo. | 2018 Aug |
2 |
| 8 |
30112106 | Selinexor reduces the expression of DNA damage repair proteins and sensitizes cancer cells to DNA damaging agents. | 2018 Jul 20 |
1 |
| 9 |
28148715 | The Exportin-1 Inhibitor Selinexor Exerts Superior Antitumor Activity when Combined with T-Cell Checkpoint Inhibitors. | 2017 Mar |
2 |
| 10 |
28819023 | Therapeutic Effects of XPO1 Inhibition in Thymic Epithelial Tumors. | 2017 Oct 15 |
1 |
| 11 |
26620414 | KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin [corrected] in prostate cancer models. | 2015 Dec 1 |
2 |